OncoTherapy Science of Japan Plans Trials Soon On Biotech Cancer Vaccine (Japan)
This article was originally published in PharmAsia News
Executive Summary
Japan's OncoTherapy Science expects to begin clinical trials this spring on a new type of cancer vaccine that relies on injecting protein fragments. The biotech technique involves genetically coded proteins injected into patients to stimulate their immune systems to attack cancers. The company has identified 16 cancer-related genes and has synthesized protein fragments and made vaccines for all of them, including ones aimed at the bladder, esophagus and lungs. (Click here for more - may require a subscription